Speedel completes 55.5M bond issue

22 January 2007

Basel, Switzerland-based biotechnology firm Speedel has successfully completed a convertible bond issue of roughly 55.5 million Swiss francs ($42.0 million) before underwriting commissions and expenses. According to the firm, demand was very strong and the conversion premium was therefore increased to 35.9% from the indicative range of 27% to 33%. Bank Vontobel AG and Bank Rud, Blass & Cie AG acted as lead manager and co-lead manager, respectively. The final terms set on the basis of the book-building process include a reference share price of 166.3 francs, a conversion price of 226 francs and a 1,000 francs denomination per bond. The payment date is January 24.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight